Karyopharm TherapeuticsKPTI -3.17%52 Median PS Value is $83.30 as of Jul. 01, 2026, which is 277567% above its 10-year median of 0.03. GuruFocus rates KPTI with a GF Score™ of 52/100 and a GF Value™ of $6.39 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 277 Biotechnology companies, Karyopharm Therapeutics ranks better than 93.86% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Karyopharm Therapeutics's Median PS Value or its related term are showing as below:
KPTI'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02 Med: 0.03 Max: 0.12
Current: 0.12
During the past 13 years, the highest Price to Median PS Value of Karyopharm Therapeutics was 0.12. The lowest was 0.02. And the median was 0.03.
KPTI's Price-to-Median-PS-Value is ranked better than 93.86% of 277
companies
in the Biotechnology industry
Industry Median: 0.63
vs KPTI: 0.12
Karyopharm Therapeutics (NAS:KPTI) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Karyopharm Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
9.755
/
83.30
=
0.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics Median PS Value Related Terms
Karyopharm Therapeutics Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KPTI vs CHRS, TARA, CNTN: Median PS Value Comparison
For the Biotechnology subindustry, Karyopharm Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 6.5277.
Karyopharm Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.761.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics (KPTI) has a Median PS Value of $83.30 as of Jul. 01, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Karyopharm Therapeutics and its competitors. This is 277567% above median its historical median of 0.03. Over the past decade, Karyopharm Therapeutics' Median PS Value has ranged from 0.02 to 0.12. According to the industry distribution chart, Karyopharm Therapeutics ranks #17 out of 277 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Karyopharm Therapeutics' Median PS Value too high?
Karyopharm Therapeutics' current Median PS Value of $83.30 is 277567% above median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.12. The Biotechnology industry median Median PS Value is 0.63. Karyopharm Therapeutics' value of $83.30 is 13122.2% above this industry median. Based on the distribution chart, Karyopharm Therapeutics ranks #17 out of 277 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Median PS Value compare to CHRS and TARA?
According to the Biotechnology industry distribution chart, Karyopharm Therapeutics ranks #17 out of 277 companies for Median PS Value. This places Karyopharm Therapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.63. Karyopharm Therapeutics' value of $83.30 is 13122.2% above this benchmark. Historically, Karyopharm Therapeutics' own Median PS Value has ranged from 0.02 to 0.12 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.63, Karyopharm Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Karyopharm Therapeutics's current Median PS Value of $83.30 is 13122.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Karyopharm Therapeutics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Karyopharm Therapeutics's current Median PS Value is $83.30, which is 277567% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.39, compared to a current price of $9.76 — trading 52.7% above its estimated fair value. The current Median PS Value is $83.30, which is 277567% above median its 10-year median of 0.03 and 13122.2% above the Biotechnology industry median of 0.63. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Median PS Value is $83.30 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?
Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued.
The current stock price of $9.76 is trading 52.7% above its estimated GF Value™ of $6.39.
GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.
Key valuation signals for KPTI:
Median PS Value: $83.30 (277567% above median its 10-year median of 0.03)
GF Value™: $6.39 vs. price of $9.76 (52.7% above fair value)
Industry Position: 13122.2% above the Biotechnology median (#17 of 277)
No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score
Get the complete analysis for KPTI
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KPTI has been successfully added to your 
